Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Avirmax CMC Inc. Launches AAV Production with Sf Rhabdovirus-free Cell Lines (Sf-RVFtm)

HAYWARD, Calif., March 22, 2023 /PRNewswire/ -- Avirmax CMC Inc. (ACI), a cGMP-licensed CDMO, is announcing the implementation of its newly-developed Sf rhabdovirus-free cell lines (under the generic trademark of Sf-RVFtm) developed for producing recombinant adeno-associated viral vectors (rAAV).

Avirmax CMC Inc. Delivers rAAV Products with Higher Viral Safety Assurance Using Sf-RVFtm Cell Lines

As an insect cell line derived from the ovarian tissue of Spodoptera frugiperda (Sf), the Sf9 cell line in concert with recombinant baculoviruses, has been widely utilized for manufacturing biologicals, including recombinant proteins, vaccines, and rAAV-based gene therapy vectors. The Sf9 cell rAAV production system has been shown to produce high yields of rAAV products containing vector genomes. However, Sf9 cell lines persistently carries Sf rhabdovirus (Sf-RV), an enveloped, negative sense and single stranded RNA (-ssRNA) virus. Although Sf-RV is an insect-specific virus and non-infectious to mammalian and human cell lines, using a Sf-RV containing Sf9 cell line for producing biologicals has potential viral safety risks that are required to be mitigated by international regulatory authorities during biopharmaceutical production.

When using serum-free suspension culture, Avirmax CMC's Sf-RVFtm cell lines have been shown to be comparable with respect to rAAV yields and quality, relative to rAAV produced using Sf-RV parental cell lines. "By implementing our Sf-RVFtm cell lines, the Sf-RV safety margin of biologic product has been increased by more than 1 billion-fold", commented Shengjiang Shawn Liu, Ph.D., DVM, chief executive and scientific officer of the company. Avirmax CMC Inc. is now using the Sf-RVFtm cell lines in rAAV manufacturing for research and clinical development purposes. Avirmax CMC Inc. is also expanding the Sf-RVFtm cell lines to the production of other modalities including vaccines and protein drugs.

Avirmax CMC Inc. (ACI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based firm working on technological solutions to challenges associated with rAAV manufacturing and testing. Please visit us at www.avirmaxCMC.com for more information.


Please contact
June Song, Associate Director for Operations
Email : business@avirmax.com
Tel: +1-510-641-0201

25503 Whitesell Street
Hayward 94545 CA

SOURCE Avirmax

These press releases may also interest you

28 mai 2023
Aromatherapy designer Michael Hulbert, who, with his wife Anna, crafted over 30 best-selling aromatherapy blends in the last decade, announces the release of his comprehensive new book and guide, "Practical Aromatherapy for Everyday Living." This...

28 mai 2023
Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics,...

28 mai 2023
The Concord Coalition said today that the budget and debt limit agreement reached by President Biden and Speaker McCarthy is a sound compromise that can be enacted in time to prevent any default on the federal government's legal obligations.  Concord...

28 mai 2023
The Honourable Marci Ien, Minister for Women and Gender Equality and Youth and Parliamentary Secretary Jenna Sudds issued the following statement today: "Period poverty is a worldwide sad reality, where many women, girls, non-binary individuals, and...

28 mai 2023
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will...

27 mai 2023
If you follow the sounds of joy and laughter echoing through BayPointe or EastPointe Hospital, you're likely to...

News published on and distributed by: